Summary
– Founded in 2018, Canadian-based Ayurcann Holdings (CSE: AYUR) (FSE: 3ZQ0) has become one of the country’s leading cannabis extraction companies, focusing on transforming cannabis and hemp to manufacture derivative products, like CBD-based oils and other related therapeutics.
– Over the COVID pandemic and into 2021, the company developed its internal processes and external partnerships with notable cannabis and CBD distributors in Canada, extending the brand’s reach across the country.
– This week, Ayurcann Holdings Corp. published an impressive report displaying the company’s yearly achievements and revenue, which increased more than ten-fold in 2021.
– For investors interested in the CBD market, Ayurcann’s internal report demonstrated the impact of Ayurcann’s latest strategic moves and shareholder confidence for further growth in 2022
About Ayurcann
In October 2018, Canada became the first country from the G20 to legalize recreational cannabis, enabling a major market to arise within the nation’s once small-scale exchanges – the Canadian Securities Exchange and the Toronto Stock Exchange. Since the decision, dozens of major Canadian and foreign companies have listed cannabis and CBD-related companies, bringing major investment into the Canadian economy.
Established in the wake of Canada’s 2018 legalization by Israeli entrepreneurs Igal Sudman and Roman Buzaker, Ayurcann Holdings has become one of Canada’s preeminent cannabis extraction companies. The rising enterprise specializing in modifying cannabis and hemp to produce derivative products, featuring healing oils and other related products, and has already exhibited the experience, expertise, and professional network in Canada and around the globe with recent partnerships. This year, Ayurcann signed an extensive agreement with Edmonton’s largest cannabis distributor “National Cannabis Distribution.” The company also maintains a digital “Ayurcann Marketplace,” operated which features a variety of medicinal products by the company’s licensed partners.
Internal Report
This week, Ayurcann Holdings Corp. announced an internal financial report, displaying the company’s annual results and revenue, ending on June 30, 2021. The report presented the company’s earnings with an increase of 1,149% – an increase of over ten-fold compared to its 2020 revenues. In terms of numbers, Ayurcann’s considerable growth included proceeds of $2,159,309 from a net profit of $7,633,656; in addition to supplying over 1 billion milligrams of cannabinoids produced from THC and CBD distillate into the Canadian cannabis market.
According to the report, Ayurcann is currently finalizing its strategic plans for its next expansion phase (Phase 2). The proposal consists of increasing its production capacity to 300,000kg of full processing ability, in addition to its yearly co-manufacturing capability of 3 million vapes, tinctures, and topical – allowing the company to further its reach throughout the Canadian provinces.
Investor’s Conclusion
For experienced CBD shareholders, Ayurcann’s latest report exudes all the characteristics of an ambitious enterprise and auspicious asset. Since the young company only entered the Canadian Securities Exchange in April of 2021 as well as the Frankfurt Securities Exchange in August 2021, its potential for long-term growth makes it a prime investment. As Ayurcann’s stock value remains low at $0.14 CAD, prospective investors should continue to monitor the promising company.
Disclaimer: I was paid to write this independent analysis of the company and it should not be construed as an investment advice of any kind. Investors should make their own decision as to the buying and selling of traded securities at their own discretion.
